Matthew Abrams, MD

Rad onc + radiology like peas and carrots 🟢 🥕

@LiangChengMD You don’t sound incredibly humbled

@jryckman3 Credentialism / focus on someone's SCOPUS profile is textbook definition of ad hominem. Only here for the meta-debate, carry on with the science debate 😀

Claude's conclusion on the subject /end

Presented Phase 1 denikitug at #AACR26. Anti-CCR8 mAb is pharmacologically active at ≥10 mg: CCR8+ intratumoral Treg depletion and Teff activation on paired biopsies. Antitumor responses in heavily pretreated pts, including anti-PD-(L)1 refractory. Manageable safety. Supports mono and combo development. @BIDMC_CancerCtr @DanaFarber

"Began ~2.5 months ago" "Recently completed" 79.2Gy in 44 fractions: BASED. His RadOnc clearly understands how to choose wisely.

@aiims2738 That’s my department!

@NiuSanford @rweichselbaum @ACRORadOnc @RadoncROVER Me too please

@rweichselbaum Can Ralph and I sign up under "other" category @ACRORadOnc @RadoncROVER?

This looks great! I’m going to sign up (if allowed).

@olsonplanner Start doing a backdoor roth IRA right away, and do it every year

What’s the best piece of financial advice you’ve ever received?

@olsonplanner Lot of truths to all of this

Academic docs who actually want to do research are getting squeezed HARD. The system says it values discovery. The paychecks say: “More RVUs, less thinking.” Let’s talk about the quiet collapse of the research track in medicine.

@olsonplanner Look for other jobs and see what they are offering

Attendings - How do you know your comp is fair?

@jryckman3 Hope that comes with a healthy pay raise

Thrilled to share that I’ve been promoted to Associate Professor! Endlessly grateful to those who’ve supported me along the way, too many to tag, and more generous than I could ever deserve. I’m looking forward to continuing to grow, learn, and give back in whatever way I can.

🚨SPRING-01🚨 🔍Locally Advanced Rectal Cancer RCT: 25 Gy x 5 ➡️ CAPOX +- Sintilimab 🔥+ Sintilimab demonstrated: ✅⬆️pCR 59% vs 33% ✅No significant adverse surgical or safety signals Time to explore with organ preserving approaches⁉️ #ASCO25

@NiuSanford ctDNA is the classic scenario of make a product then determine its usefulness. All it does is provide anxiety to patients

DYNAMIC III: another study showing ctDNA prognostic, but not predictive.
 At this point, the main scenario I see for ctDNA guiding treatment decision making in CRC is potentially selecting patients for non-operative management after chemo/chemoRT in rectal cancer.

X-torial: Cleaning up the misinformation about @JoeBiden and #ProstateCancer that I am reading everywhere. The purpose of this is to provide education from someone who treats and studies PCa for a living, lead the USA @NCCN PCa guidelines, hold leadership in @NRGonc @theNCI @US_FDA and dedicated my career to help men and their families suffering from PCa @nytimes @WSJ @FoxNews @CNN @NBCNews @Reuters @ASCO @PCFnews @DeptofDefense

✨ Practice-changing for gallbladder cancer? A randomized phase 3 trial from 🇮🇳 evaluated NACTRT vs NACT in locally advanced GBC (T3/T4, N1, liver infiltration). Results: ✂️ R0 resection: 51.6% (NACTRT) vs 29.7% (NACT) p=0.01 ⏳ Median OS: 21.8 vs 10.1 mo HR: 0.56 (95% CI 0.37–0.84), p=0.006 ⏱ EFS: 10.6 vs 4.9 mo HR: 0.58 (95% CI 0.39–0.85), p=0.006 5-year OS: 27% vs 18% Grade 3+ post-op morbidity: similar (~18–28%) Conclusion: NACTRT significantly improves resectability & long-term survival in unresectable LAGBC. #GIonc #GallbladderCancer #ASCO25 #OncoTwitter @NiuSanford @5_utr @ASCO

Wow, this trial showed no OS benefit to FOLFIRINOX vs. single agent gemcitabine in locally advanced pancreas cancer (different than adjuvant & metastatic trials - both w OS improvement!) PFS increased by 2 mo, but this came at cost of increased toxicity, $, treatment burden.

@Hatchisyodaddy @olsonplanner False. Get more than you think you need, as soon as you can

@olsonplanner Have been told it’s probably not necessary right out of residency. Any rule of thumb for when it is time to start looking into it? 1M net worth?

Physicians - How much umbrella insurance do you have?

@NiuSanford I’m much more likely to offer it now, especially if any concern for excess toxicity

PLATO ACT 4: Ph II RCT of 50.4 vs. 41.4 Gy for T1-2 (<4 cm) N0 anal SCC. No difference in 3-year local recurrence (primary endpoint) or OS, & better toxicity/QOL with dose-reduction. Should 41.4 Gy be a SOC option (ahead of Ph III DECREASE trial reporting)? #ESTRO25

⚡️⚡️NEW STUDY - presented today at #ARS2025 in an oral talk by MS2 Yarelis Roque-Reyes from UCC School of Medicine, PR 🧠💥 Does whole brain RT (WBRT) help patients hospitalized with symptomatic leptomeningeal disease (LMD)? Our @MountSinaiRO study suggests: rarely — and in reality, it may be more harmful to patients’ quality of life and end-of-life care. 🧵👇 #radonc #neuroonc #endoflifecare #ARS2025 LMD is a devastating CNS complication with 3–6 mo survival. WBRT is often used for palliation — but for patients sick enough to need hospital admission, we asked: 👉 Does it actually help? We reviewed 58 such patients (2014–2023). Here’s what we found ⬇️ 📊 Symptom response after WBRT: ❌ 74% worsened ➖ 21% no change ✅ Only 5% improved 💀 Short-term mortality: 40% at 30 days 60% at 60 days 76% at 90 days 📉 ECOG declined in 79% ⏳ 30% spent >⅓ of their remaining lifespan on treatment — often in the hospital 🎯 Our takeaways ➡️ In hospitalized patients with symptomatic LMD, WBRT provides little to no clinical benefit ➡️ with few exceptions, best supportive care — not burdensome WBRT — should be the priority ➡️time to rethink WBRT in hospitalized pts with LMD? 👏 Congrats to Yarelis Roque-Reyes on her #ARS2025 oral talk! @sindhu_kunal @MountSinaiRO @QuadShotNews